We’re excited to share that abc biopply is now a new member of EUROoCS!

abc biopply AG is a Swiss biotechnology company pioneering nextgeneration humanized multiorganoid and NAM (New Approach Methodologies) technologies. With its proprietary 3D CoSeedis™ multi-organoid models, the company provides highly predictive preclinical organoid CRO services across therapeutic areas such as oncology, neurology, hepatology, metabolic disease, and more. Their humanrelevant models help close the translational gap and significantly reduce reliance on animal testing—accelerating drug discovery and development.

By joining EUROoCS – the European OrganonChip Society, abc biopply becomes part of a vibrant, international community dedicated to advancing OrganonChip research, fostering collaboration, and driving scientific innovation across academia, industry, healthcare, and regulatory stakeholders.

Both organizations share a strong mission: improving the predictiveness, scalability, and human relevance of preclinicalresearch. EUROoCS provides a powerful platform for knowledge exchange, networking, and scientific progress—while abc biopply brings deep expertise in standardized, scalable multiorganoid systems that complement and strengthen the OrganonChip ecosystem.

 
Together, this alignment will help push forward innovative, humancentered research tools that support better, faster, and more ethical drug development.